Mark Jason Heath Ellison - 27 Jan 2023 Form 4 Insider Report for OPIANT PHARMACEUTICALS, INC.

Role
Chief Development Officer
Signature
/s/ Mark Jason Heath Ellison
Issuer symbol
N/A
Transactions as of
27 Jan 2023
Net transactions value
-$12,359
Form type
4
Filing time
31 Jan 2023, 15:21:37 UTC
Previous filing
09 Jan 2023
Next filing
03 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OPNT Common Stock Sale $12,359 -610 -3.2% $20.26 18,751 27 Jan 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.